Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
{"title":"Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.","authors":"","doi":"10.1016/j.jacl.2024.04.065","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/Synopsis</h3><p>Multifactorial chylomicronemia syndrome (MCS), also known as type V hyperlipoproteinemia, is a rare polygenic disorder characterized by severe hypertriglyceridemia. It is triggered by uncontrolled diabetes mellitus (DM), obesity, metabolic syndrome, and certain medications. It is not known whether hypertriglyceridemia associated with MCS accelerates atherosclerotic cardiovascular disease (ASCVD).</p></div><div><h3>Objective/Purpose</h3><p>To speculate the relationship between ASCVD in a patient with hypertriglyceridemia caused by MCS, uncontrolled DM, and polymorphic APOA5, APOE2/4, LMF1 and LP(a) intron mutations.</p></div><div><h3>Methods</h3><p>We present a 60-year-old male with PMH of severe hypertriglyceridemia (highest 6000mg/dL) with acute pancreatitis at age 40, CAD s/p CABG at age 50, PAD s/p bypass at age 57, HTN, mixed hyperlipidemia, uncontrolled DM, and family history of premature ASCVD. He was subsequently followed at the advanced lipid clinic where his medications included rosuvastatin, ezetimibe, evolocumab, fenofibrate, and icosapent ethyl. He underwent advanced genetic testing with GBinsight.</p></div><div><h3>Results</h3><p>GBinsight identified various polymorphic genes causing hypertriglyceridemia as follows:</p><p>APOA5 - c.*158C&gt;T(rs2266788)</p><p></p><ul><li><span>-</span><span><p>This variant is found in ∼10% of the global population and has been associated with hypertriglyceridemia by multiple genome-wide association studies.</p></span></li></ul><p>APOA5 - c.457G&gt;A(p.Val153Met)(rs3135507)</p><p></p><ul><li><span>-</span><span><p>This variant is found in ∼5-10% of the global population and has been associated with modest hypertriglyceridemia and lower HDL-C in the UKBiobank cohort.</p></span></li></ul><p>APOE2</p><p></p><ul><li><span>-</span><span><p>This allele has been associated with a reduction of the major lipolytic enzyme, lipoprotein lipase (LPL) activity, causing modest hypertriglyceridemia.</p></span></li></ul><p>LMF1 - p.Arg354Trp(rs143076454)</p><p></p><ul><li><span>-</span><span><p>This variant is found in ∼2% of the global population, and has been associated with a reduction of LPL activity causing modest hypertriglyceridemia.</p></span></li></ul><p>GBinsight identified various pathogenic genes causing elevated Lp(a) as follows:</p><p>LPA - Heterozygous for intron c.3947+467T&gt;C(rs10455872)</p><p></p><ul><li><span>-</span><span><p>This variant serves a genetic proxy for short isoforms and is strongly associated with increased Lp(a), total and LDL-cholesterol levels, and increased ASCVD risk.</p></span></li></ul><p>APOE4</p><p></p><ul><li><span>-</span><span><p>This allele is associated with increased Lp(a) levels.</p></span></li></ul></div><div><h3>Conclusions</h3><p>We speculate that the combination of these polymorphisms works together to increase risk of severe hypertriglyceridemia, also known as MCS. Several smaller studies have suggested MCS is caused by either of the two major mechanisms: (1) some combination of minor genetic polymorphisms, or (2) presence of a single genetic mutation in one of the five genes regulating triglyceride metabolism including LPL, APOC2, APOA5, GPHIBP1, and LMF1.</p><p>We postulate acceleration of ASCVD in our patient with MCS was multifactorial, including deposition of atherogenic triglyceride rich lipoproteins within blood vessels, in addition to the independent risk factor of elevated Lp(a). Furthermore, he had poorly controlled DM and insulin resistance owing to the increased circulating triglycerides, which further increased endothelial lining damage and accelerated ASCVD.</p></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287424001120","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/Synopsis

Multifactorial chylomicronemia syndrome (MCS), also known as type V hyperlipoproteinemia, is a rare polygenic disorder characterized by severe hypertriglyceridemia. It is triggered by uncontrolled diabetes mellitus (DM), obesity, metabolic syndrome, and certain medications. It is not known whether hypertriglyceridemia associated with MCS accelerates atherosclerotic cardiovascular disease (ASCVD).

Objective/Purpose

To speculate the relationship between ASCVD in a patient with hypertriglyceridemia caused by MCS, uncontrolled DM, and polymorphic APOA5, APOE2/4, LMF1 and LP(a) intron mutations.

Methods

We present a 60-year-old male with PMH of severe hypertriglyceridemia (highest 6000mg/dL) with acute pancreatitis at age 40, CAD s/p CABG at age 50, PAD s/p bypass at age 57, HTN, mixed hyperlipidemia, uncontrolled DM, and family history of premature ASCVD. He was subsequently followed at the advanced lipid clinic where his medications included rosuvastatin, ezetimibe, evolocumab, fenofibrate, and icosapent ethyl. He underwent advanced genetic testing with GBinsight.

Results

GBinsight identified various polymorphic genes causing hypertriglyceridemia as follows:

APOA5 - c.*158C>T(rs2266788)

  • -

    This variant is found in ∼10% of the global population and has been associated with hypertriglyceridemia by multiple genome-wide association studies.

APOA5 - c.457G>A(p.Val153Met)(rs3135507)

  • -

    This variant is found in ∼5-10% of the global population and has been associated with modest hypertriglyceridemia and lower HDL-C in the UKBiobank cohort.

APOE2

  • -

    This allele has been associated with a reduction of the major lipolytic enzyme, lipoprotein lipase (LPL) activity, causing modest hypertriglyceridemia.

LMF1 - p.Arg354Trp(rs143076454)

  • -

    This variant is found in ∼2% of the global population, and has been associated with a reduction of LPL activity causing modest hypertriglyceridemia.

GBinsight identified various pathogenic genes causing elevated Lp(a) as follows:

LPA - Heterozygous for intron c.3947+467T>C(rs10455872)

  • -

    This variant serves a genetic proxy for short isoforms and is strongly associated with increased Lp(a), total and LDL-cholesterol levels, and increased ASCVD risk.

APOE4

  • -

    This allele is associated with increased Lp(a) levels.

Conclusions

We speculate that the combination of these polymorphisms works together to increase risk of severe hypertriglyceridemia, also known as MCS. Several smaller studies have suggested MCS is caused by either of the two major mechanisms: (1) some combination of minor genetic polymorphisms, or (2) presence of a single genetic mutation in one of the five genes regulating triglyceride metabolism including LPL, APOC2, APOA5, GPHIBP1, and LMF1.

We postulate acceleration of ASCVD in our patient with MCS was multifactorial, including deposition of atherogenic triglyceride rich lipoproteins within blood vessels, in addition to the independent risk factor of elevated Lp(a). Furthermore, he had poorly controlled DM and insulin resistance owing to the increased circulating triglycerides, which further increased endothelial lining damage and accelerated ASCVD.

多因素乳糜微粒血症综合征 (MCS)、脂蛋白(a)升高、APOE2/4 基因型和糖尿病患者的动脉粥样硬化加速。
背景/简介多因素乳糜微粒血症综合征(MCS)又称 V 型高脂蛋白血症,是一种罕见的多基因疾病,以严重的高甘油三酯血症为特征。未控制的糖尿病(DM)、肥胖、代谢综合征和某些药物会诱发这种疾病。目标/目的推测一名由 MCS、未控制的 DM 和多态 APOA5、APOE2/4、LMF1 和 LP(a) 内含子突变引起的高甘油三酯血症患者的 ASCVD 之间的关系。方法我们为您介绍一名 60 岁男性患者,他患有严重高甘油三酯血症(最高 6000 毫克/分升)的 PMH,40 岁时曾患急性胰腺炎,50 岁时曾接受过 CAD 手术/CABG 手术,57 岁时曾接受过 PAD 手术/搭桥手术,患有高血压、混合型高脂血症、未控制的 DM 和过早发生 ASCVD 的家族史。随后,他在高级血脂诊所接受了随访,服用的药物包括洛伐他汀、依泽替米贝、依沃洛库单抗、非诺贝特和伊可新戊酯。他接受了 GBinsight 的高级基因检测。结果GBinsight 发现了导致高甘油三酯血症的多种多态性基因,具体如下:APOA5 - c.*158C>T(rs2266788)- 这种变异在全球人口中的发现率为 10%,多项全基因组关联研究表明它与高甘油三酯血症有关。G>A(p.Val153Met)(rs3135507)-该变异在全球 5%至 10%的人群中发现,在英国生物银行队列中,该变异与中度高甘油三酯血症和较低的高密度脂蛋白胆固醇有关。APOE2-该等位基因与主要脂肪分解酶脂蛋白脂肪酶(LPL)活性降低有关,导致中度高甘油三酯血症。LMF1 - p.Arg354Trp(rs143076454)-该变异在全球 2% 的人群中发现,与 LPL 活性降低有关,可引起轻度高甘油三酯血症。+APOE4-该等位基因与脂蛋白(a)水平升高有关。结论我们推测,这些多态性的组合共同作用增加了严重高甘油三酯血症(又称 MCS)的风险。一些较小的研究表明,MCS 是由以下两种主要机制中的任何一种引起的:(1) 小基因多态性的某种组合,或 (2) 调节甘油三酯代谢的五个基因(包括 LPL、APOC2、APOA5、GPHIBP1 和 LMF1)中某一个基因的单基因突变。我们推测,我们的 MCS 患者的 ASCVD 加速是多因素的,除了 Lp(a) 升高这一独立风险因素外,还包括血管内富甘油三酯脂蛋白的致动脉粥样硬化沉积。此外,由于循环甘油三酯增加,他的糖尿病和胰岛素抵抗控制不佳,这进一步加重了血管内皮损伤,加速了急性心血管疾病的发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信